Scientists from Biosantech Co., a private company based in France, recently announced that its HIV vaccine candidate is safe and not toxic for HIV patients.
This announcement is based on results from a study involving 48 HIV-positive patients who were enrolled in the company’s double-blind study that took place in France. The 48 patients were divided into four groups. One of these groups, made up of 12 people, received a placebo. The remaining patients were divided into the three groups that received varying amounts of the HIV vaccine. The data from this study was then presented to the International Conference on Retroviruses and Novel Drugs in Chicago.
Sonia Escaich, the executive director of Biosantech, stated that none of the patients experienced adverse side effects or drug interactions.
According to Corinne Treger, chief executive officer of Biosantech, further data and details from the Phase II study will be published by the end of the summer. She said the data’s preliminary analysis proves that the vaccine candidate is safe for HIV-positive patients.
The positive results from this study will enable researchers to continue their studies and perhaps create combinations of IMMUNOREX, a treatment from Donatien Mavoungou, to boost the immune system.
“It is our hope we can develop a therapy that can make a difference to the people suffering from this disease,” Treger said.